|1.||Shi, Jing: 2 articles (12/2006 - 10/2006)|
|2.||Liu, Ming: 1 article (01/2011)|
|3.||Teng, Junfang: 1 article (01/2011)|
|4.||Wu, Taixiang: 1 article (01/2011)|
|5.||Hao, Zilong: 1 article (01/2011)|
|6.||Liu, Guan J: 1 article (01/2011)|
|7.||Yang, Weimin: 1 article (01/2011)|
|8.||Wu, Bo: 1 article (01/2011)|
|9.||Tian, Jin-zhou: 1 article (12/2006)|
|10.||Wang, Yong-yan: 1 article (12/2006)|
01/01/1998 - "Different pharmacological properties of almitrine-raubasine show that this combination may be a good therapy for the treatment of age-related cerebral disorders and functional rehabilitation after stroke. "
01/01/1998 - "In the acute phase of stroke, positron emission tomography showed, in man, that almitrine-raubasine helps normalize the ischemic penumbra area, as shown by an improvement in the coupling between oxygenation and perfusion. "
01/01/1998 - "Without discussing the complexity of clinical trials in both the areas of cognitive disorders and stroke, we shall present two studies demonstrating the beneficial effects of almitrine-raubasine against cognitive impairments. "
03/01/2004 - "The results indicate that almitrine + raubasine can accelerate neurological function recovery after stroke to some degree and is well tolerated."
01/01/1998 - "Almitrine-raubasine has been used to improve functional rehabilitation after stroke for some time in China. "
|2.||Multi-Infarct Dementia (Dementia, Multi Infarct)
12/01/2002 - "Memory function were assessed at baseline and endpoint using memory subscales of a battery of New Psychometric Tests (Chinese version) including mini-mental state examination (MMSE), verbal memory, and non-verbal memory, etc. After treatment, the mean scores of verbal memory in the Hopkins Verbal Learning Test (P<0.05) and total memory scores of memory items (P<0.001) in JNN group increased significantly; and improvement in episodic memory function including story recall (immediate and delayed), delayed word recall, verbal learning and verbal recognition and visual recognition in the JNN group was better than that in the duxil control group, suggesting that JNN can obviously improve memory function for the patients with mild or moderate multi-infarct dementia."
12/01/2002 - "Forty patients with multi-infarct dementia (MID) were randomly assigned to the treatment group (25 cases) treated with Jian Nao Ning (JNN) and the duxil control group (15 cases). "
|3.||Brain Ischemia (Cerebral Ischemia)
02/01/1988 - "[Evaluation of acute and chronic cerebral ischemia in man by positron and single photon emission tomography: application to the study of duxil]."
02/01/1988 - "[Experimental models in cerebral ischemia: application to the study of duxil]."
01/01/1990 - "Progress in understanding the pathophysiology of cerebral ischemia: the almitrine-raubasine approach."
01/01/1990 - "Positron emission tomography and oxygen-15 were used to evaluate the effect of almitrine-raubasine combination on cerebral blood flow and oxidative metabolism in patients with cerebral ischemia. "
12/01/2006 - "Rats were divied into four groups: sham-group, cerebral ischemia model-group, GETO-group(6. 1 g x kg(-1) x d(-1) )and Duxil-group (7.3 mg x kg(-1) x d(-1)). "
03/24/1983 - "At that dosage level, Duxil may therefore be considered an active treatment of hypoxia associated with old age."
03/24/1983 - "Their functional activity may be maintained, and this would justify the use of Duxil in mental and behavioural disorders of cerebral senescence and cerebro-vascular diseases related to hypoxia."
03/24/1983 - "Pharmacological studies of Duxil in healthy animals and experimental models have demonstrated that the drug increases arterial oxygen supply, improves tissue oxygenation and is capable of correcting vascular and metabolic disorders due to hypoxia. "
01/01/1980 - "[Effect of a tissue oxygenator (almitrine + raubasine) on the metabolism of 2,3-diphosphoglycerate of rabbits submitted by hypoxia]."
03/24/1983 - "After administration of Duxil to animals whose brain has been severely deprived of oxygen by experimental anoxia or ischaemia, the oxygen supply is sufficient for the brain cells to take up their preferential substrate (glucose) and to use it through the most energy-producing aerobic pathway. "
01/01/2011 - "Due to the low methodological quality of included trials, small number of trials and probable publication bias, this review did not provide sufficient evidence to support the routine use of Duxil for the treatment of patients with dementia. "
01/01/2011 - "Randomised controlled trials studying the efficacy and safety of Duxil for dementia were included, irrespective of blinding, publication status, or language. "
01/01/2011 - "To determine the clinical efficacy and safety of Duxil in the treatment of patients with dementia. "
01/01/2011 - "Almitrine-Raubasine combination for dementia."
01/01/2011 - "Almitrine-raubasine combination (brand name Duxil), has been considered as an alternative treatment for dementia. "
|1.||raubasine drug combination almitrine (Duxil)
|4.||2,3-Diphosphoglycerate (2,3 Bisphosphoglycerate)
|7.||Glial Fibrillary Acidic Protein
|9.||10-N-nonylacridinium orange (NAO)